NEW YORK (GenomeWeb) – DiaSorin announced on Tuesday that the US Food and Drug Administration has provided 510(k) clearance of the firm's Simplexa C. difficile Direct Assay for marketing in the US.

The assay has been available outside the US since November and runs on DiaSorin's Liaison MDX benchtop instrument, which provides clinically validated, real-time PCR results, the Italian in vitro diagnostic firm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.